Boehringer Ingelheim
My giotrif logo

banner.png

WEBINAR VIDEOS

Document ID: PC-MY-101296

Speaker: Dr. Yap Beng Khiong

Evidence for Sequential Therapy in EGFR M+ NSCLC

Join Dr. Yap Beng Khiong as he brings us through the evidence for sequential therapy in EGFR M+ NSCLC. Dr Yap summarises findings from the prospective pooled analysis of the LUX-Lung trials and the GioTag study, where he highlights the rationale of sequential afatinib, followed by osimertinib therapy in the treatment of EGFR M+ NSCLC.

Expert Conversations

Malaysia Region Tumour Heterogeneity in Lung Cancer Asian setting
MYEEE||EGFR TKI-related Dermatological Adverse Events
MYEEE||Evidence for Sequential Therapy in EGFR M+ NSCLC
MYEEE||Effectiveness of Dose Modification Strategies with Afatinib
MYEEE||Strategies in Managing EGFRM+ NSCLC
Malaysia Region Treatment stratergy with EGFR-TKIs Asian setting
Running the Marathon: Updated Evidence on Sequential EGFR TKI Approach in NSCLC (Q&A session)
Running the Marathon: Updated Evidence on Sequential EGFR TKI Approach in NSCLC (Presentation)
MYEEE||PeRsonalized apprOach in Lung adenocarciNoma with EGFR-TKI therapy (PROLONG)
Uncovering the Uncommon: Efficacy of Afatinib in Uncommon and Compound Mutations
Taking Cancer On Webinar – Let’s TOAST to Maximising Time on EGFR-TKI Therapy (Lecture)
Taking Cancer On Webinar – Let’s TOAST to Maximising Time on EGFR-TKI Therapy (Q&A)

Speaker

Dr-Yap-Beng-Khiong-speaker.png

Dr Yap Beng Khiong

Consultant Clinical Oncologist MBChB, MRCP, FRCP, FRCR Subang Jaya Medical Centre, Malaysia

RELATED CONTENT